Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Celsion (CLN AMEX) was CELN -- Ignore unavailable to you. Want to Upgrade?

To: Numberspro who wrote (895)	9/14/2003 10:52:20 AM
From: Tech Master	Respond to of 966

The most recent private placement wasn't unusually large and the terms were favorable imo for the company. The bulk of the capital recently announced came from the exercise of warrants issued as part of previous fundraising efforts. It is my understanding that CLN may not need to go to the well for additional capital again if their business plan unfolds as expected. FWIW- I don't expect to see Volk be a significant seller. He had a successful career prior to CLN and from what I can tell "doesn't need the money" but pure speculation on my part. I believe that the stock will increase 2x within the next six months and I have a 2 yr. target range of $3.50-$5.00 with a 70% probability assigned to both estimates. I see downside risk limited to .90 and the probability of FDA approval for BPH as 90-95%. Significant consideration should be given to other aspects of the pipeline. Phase II (of II) breast cancer trials have yielded dramatic results. As reported, 25 of 26 patients had full tumor ablation (death)with clean margins. It is my understanding that the other patient aborted the trial but had to be recorded anyway. I reserve the right to be wrong on that account, but even so, the treatment results indicate a protocol that will dramatically change breast cancer treatment. Prostate cancer trials using heat sensitive liposomes have begun. If the protocol mirrors the animal results (highly likely), we will be sitting pretty. The potential for the creation of a multi-drug pipeline beyond doxirubicin is very high if the results warrant expansion (also highly likely). Like many that have followed the company for quite some time, I will continue to build up my position on any weakness as I see a dramatic shift in the prospects of CLN vs. any other time in their corporate history. While the i's need dotting and the t's need to be crossed, we are well on our way to much higher valuations in the near and longer terms. All JHMO and best of luck.